Galera Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 59.08 million compared to USD 62.22 million a year ago. Basic loss per share from continuing operations was USD 1.33 compared to USD 2.3 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1761 USD | -0.56% | -5.32% | +21.11% |
03/04 | North American Morning Briefing : Powell Awaited -2- | DJ |
28/03 | Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+21.11% | 9.58M | |
+3.91% | 109B | |
+10.87% | 105B | |
+0.12% | 22.25B | |
-13.14% | 22.09B | |
-8.14% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- GRTX Stock
- News Galera Therapeutics, Inc.
- Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023